TABLE 1.
Antibody response to CVB3-PL2-Ad2L1 infection in micea
| Antiserumb | Virus-neutralizing titerc
|
Virus-binding titerd (Ad2) | |
|---|---|---|---|
| CVB3/0 | Ad2 | ||
| CVB3-PL2-Ad2L1-1x | 1/16 | <1/2 | 1/20 |
| CVB3-PL2-Ad2L1-2x | 1/32 | 1/4 | 1/100 |
| CVB3-PL2-Ad2L1-3x | 1/64 | 1/8–1/16 | 1/1,000 |
| CVB3/0-1x and CVB3-PL2-Ad2L1-2x | 1/128 | 1/16–1/32 | 1/5,000–1/10,000 |
| CVB3/0-2x and CVB3-PL2-Ad2L1-2x | 1/128 | 1/32 | 1/10,000 |
| Hyperimmune CVB3 | >1/1,000 | ||
| Hyperimmune Ad2 | >1/1,000 | >1/10,000 | |
Mice were inoculated once (CVB3-PL2-Ad2L1-1x), twice (CVB3-PL2-Ad2L1-2x; 14 days apart), or three times (CVB3-PL2-Ad2L1-3x; each 14 days apart) with 5 × 105 TCID50 of virus. For studies of anti-Ad2 responses in CVB3/0-immunized mice (inoculated once or twice, 14 days apart), mice were challenged twice with CVB3-PL2-Ad2L1.
Pooled sera were measured for neutralizing as well as binding antibodies as described in the text. Hyperimmune CVB3/0, polyclonal horse anti-CVB3 serum (ATCC); Hyperimmune Ad2, polyclonal mouse serum obtained 2 weeks after the last of four inoculations (each 3 weeks apart) with Ad2.
Neutralizing-antibody titers are expressed as the reciprocal of the highest antibody solution preventing virus-induced cytopathic effects in three of three wells.
ELISA binding antibody titers were defined as the highest serum dilution giving an absorbance value of more than 0.2 optical density unit at 405 nm above control levels.